| Company* (Country; Symbol) |
Product | Description | Indication | Status (Date) |
| Bayer Healthcare AG (Germany) and Johnson & Johnson Pharmaceutical Research & Development LLC | Rivaroxaban | Oral, once-daily anti-coagulant | To prevent venous throm-boembolism in patients under-going total hip or knee replacement surgery | Phase III data showed it was significantly more effective than enoxaparin (12/11) |
| Celgene Corp. (CELG) | Revlimid (FDA-approved) | Lenalidomide; an analogue of thalidomide | Multiple myeloma; non-Hodgkin's lymphoma | Phase III of Revlimid and dexamethasone showed an overall response rate of 85.3%, compared with 51.3% in the dexamethasone only group (12/10); showed activity in the initial analysis of the first 46 patients of a 200-patient Phase II trial (12/11) |
| Cell Therapeutics Inc. (CTIC) | Pixantrone | An anthracenedione | Aggressive non-Hodgkin's lymphoma | Phase II/III data showed patients experienced less severe toxicities than those treated with standard doxorubicin-based therapy (12/11) |
| ChemGenex Pharmaceuticals Ltd. (Australia; CXSP) | Ceflatonin | Omacetaxine mepesuccinate | Chronic myeloid leukemia | Phase II/III data showed both complete hematologic and cyto-genetic responses lasting more than a year (12/10) |
| Cyclacel Pharmaceuticals Inc. (CYCC) | CYC682 | Sapacitabine; an oral nucleoside analogue | Acute myelogenous leukemia and myelodysplastic syndromes | Phase I data demonstrated a favorable safety profile (12/10) |
| Cytokinetics Inc. (CYTK) | SB-743921 | Small-molecule kinesin spindle protein inhibitor | Non-Hodgkin's lymphoma | Phase I/II data showed it was well tolerated without prophylactic granulocyte-colony stimulating factor (12/10) |
| Exelixis Inc. (EXEL) | XL019 | Small molecule that selectively inhibits the tyrosine kinase JAK2 | Myelofibrosis | Phase I data showed a reduction in spleen size of 33% to 100% in five of six patients evaluated; reduction in erythropoietin-independent colony formation of up to 39% and up to 100% in two patients; relief of constitutional symptoms; and reduction in the number of cells with the JAK2 V617F mutation (12/11) |
| F. Hoffmann-La Roche Ltd. (Switzerland) | MabThera | Rituximab | Chronic lymphocytic leukemia | Phase II data showed 92% of patients achieved a response (12/11) |
| Gloucester Pharmaceuticals Inc.* | Romidepsin | A histone deacetylase inhibitor | Multiple myeloma | Phase I/II data of romidepsin with Velcade and dexamethasone showed an overall response rate of 80% (12/11) |
| Hana Biosciences (HNAB) | Marquibo | Vincristine sulfate injection, Optisome | Acute lymphoblastic leukemia | With or without pulse dexametha-sone Marqibo appears to have clinically meaningful activity in heavily pre-treated adults (12/10) |
| ImmunoGen Inc. (IMGN) | AVE9633 | Consists of DM4 cell-killing agent and huMy9-6 CD33-binding antibody | Relapsed/refractory acute myeloid leukemia | AVE9633 demonstrated evidence of biological activity in multiple patients; it was generally well tolerated (12/10) |
| Incyte Corp. (INCY) | INCB18424 | Orally available janus-associated kinase inhibitor | Myelofibrosis | Phase I/II data demonstrated that mean reduction in spleen size reached 52% in the first month and 86% in the third (12/11) |
| Innovive Pharmaceuticals Inc. (OTC BB:IVPH) | INNO-305 | A Wilms Tumor Protein heteroclitic peptide immunotherapeutic vaccine | Myeloid and throacic neoplasms | Pilot study data suggested repeat administration is well tolerated and immune response can be elicited following three vaccinations (12/10) |
| Keryx Biopharma-ceuticals Inc. (KERX) | KRX-0401 | Perifosine; oral agent that modulates AKT and other signal transduction pathways | Multiple myeloma | Phase I data of Perifosine in combination with Velcade showed clinical activity (12/10) |
| Kosan Biosciences Inc. (KOSN) | KOS-953 | Tanespimycin | Multiple myeloma | Phase Ib data showed a lower response rate than the company reported earlier, but it may not affect the Phase III program, already under way (12/10); Phase Ib data of KOS-953 in combination with Velcade showed durable antitumor activity and tolerability (12/10) |
| Millennium Pharmaceuticals Inc. (MLNM) | Velcade (FDA-approved) | Bortezomib | Multiple myeloma | Interim results from a 256-patient Phase III trial of Velcade with thalidomide and dexamethasone showed a fourfold increase in complete remission for patients with previously untreated multiple myeloma, compared with thalidomide and dexamethasone alone (12/10) |
| Pharmacyclics Inc. (PCYC) | Xcytrin | Injection; motexafin gadolinium | Non-Hodgkin's lymphoma | Phase I/II data demonstrated a 59% overall response rate in patients treated with Xcytrin in combination with Zevalin; Overall response rate for Rituxan-refractory patients was 86% (12/10) |
| Pharmion Corp. (PHRM) | Thalomid (FDA-approved) | Thalidomide | Multiple myeloma | Data from a 232-patient Phase III trial showed the addition of thalidomide to standard treatment of melphalan-prednisone improved survival by 17.6 months in 75 or older compared with melphalan-prednisone alone (12/10) |
| Pharmion Corp. (PHRM) | Vidaza | Azacitidine for injection | Myelodysplastic syndrome | Phase II data demonstrated safety and response profiles consistent with those achieved with the FDA-approved seven-day regimen (12/11) |
| ProMetic Life Sciences Inc. (Canada; TSX:PLI) | PBI-1402 | Orally active low molecular weight synthetic compound with erythropoiesis-stimulating activity | Chemotherapy-induced anemia | Phase II data showed it induced a significant increase in red blood cell count and hemoglobin level in patients (12/11) |
| Seattle Genetics Inc. (SGEN) | SGN-33 | Lintuzumab | Acute myeloid leukemia | Phase Ia data demonstrated multiple complete remissions at well-tolerated doses (12/10) |
| Sunesis Pharmaceuticals Inc. (SNSS) | SNS-595 | Cell-cycle inhibitor | Acute leukemia | Phase I data showed it was generally well tolerated (12/10) |
| Telik Inc. (TELK) | Telintra | Ezatiostat HCl tablets | Myelodysplastic syndrome | Phase I data showed it was well tolerated and no dose-limiting toxicities were observed (12/10) |
| ThromboGenics NV (Belgium; BR:THR) | TB-402 | A recombinant human monoclonal antibody | Venous thromboembolic disorders | Phase I data showed it is safe and well tolerated and no serious adverse events were reported (12/11) |
| Vion Pharmaceuticals Inc. (VION) | Cloretazine | VNP40101M | Acute myelog-enous leukemia | Pivotal Phase II data showed the product achieved its targeted response rate (12/10) |
| Xanthus Pharmaceuticals Inc.* | Xanafide | Amonafide malate | Multidrug-resistant leukemia and myeloma and secondary acute myeloid leukemia | Xanafide demonstrated that the uptake, efflux and cyto-toxicity of Xanafide were un-affected by MDR proteins expressed in AML cells (12/10) |
| ZymoGenetics Inc. (ZGEN) | IL-21 | Interleukin-21 | Relapsed low-grade B cell lymphoma | Phase I data of IL-21 in combination with rituximab showed it was well tolerated and resulted in anti-lymphoma activity (12/10) |
|
Notes: * Privately held. Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.BR = Brussels Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.